# Optimizing Lung Cancer Treatment in HIV Infected Persons

> **NIH NIH R01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $533,267

## Abstract

PROJECT SUMMARY
The overall goal of this project is to improve the management of HIV infected (HIV+) lung cancer patients.
Lung cancer is the leading cause of cancer death in older HIV+ patients. Up to 30% of lung cancer cases are
diagnosed at a loco-regional stage (with expected increases due to the implementation of lung cancer
screening in the HIV+ population), can be treated with a curative intent, and may experience relatively good
long-term survival. Despite this, HIV+ lung cancer patients experience lung cancer treatment disparities and
have poorer lung cancer outcomes. The risk/benefit ratio of cancer therapies can be substantially altered in
HIV+ patients because of differences in treatment toxicity, tumor aggressiveness, functional status, life
expectancy, and quality of life. Unfortunately, patients with comorbidities such as HIV are consistently excluded
from randomized controlled trials (RCTs) generating an important gap in knowledge regarding their
management. Lack of data relevant to HIV+ patients has profound negative impact including under treatment,
increased morbidity, and decreased survival. Thus, optimizing the management of HIV+ lung cancer patients is
a major public health priority. In this study, we will use simulation modeling, an approach complementary to
RCTs, to determine the optimal treatment of early stage HIV+ lung cancer patients. The Specific Aims are to:
1) enhance and validate the Lung Cancer Policy Model (LCPM) to simulate the management and subsequent
outcomes of HIV+ patients with loco-regional non-small cell lung cancer (NSCLC); 2) determine the optimal
management for stage I NSCLC in HIV+ patients; 3) find the optimal indications for adjuvant chemotherapy for
stage II-IIIA NSCLC in HIV+ patients; and 4) identify optimal management strategies for stage I-IIIA NSCLC in
HIV+ patients with severe cardiac, pulmonary, renal or hepatic comorbidities. To achieve these Aims, we will
use an enhanced version of the LCPM, a well-validated mathematical model of lung cancer progression. In
Aim 1, we will use data from several population-based HIV+ cohorts to substantially enhance, calibrate, and
validate the LCPM by incorporating an HIV natural history module, as well as HIV-specific parameter
modifications for functional status, frailty, cancer treatments, complications of surgery and chemotherapy
toxicity, outcomes, survival and quality of life. Then, we will assess the optimal management, in terms of
reducing toxicity and maximizing survival and quality of life, of HIV+ patients with early stage lung cancer. Our
study is innovative in providing HIV-specific cancer treatment guidance, as well as in applying modeling
approaches mostly used to evaluate cancer screening, to the optimization of lung cancer therapies. The results
of the study will directly inform the management of large numbers of HIV+ lung cancer patients, a vulnerable
and understudied group that currently experience substantially worse outcomes.

## Key facts

- **NIH application ID:** 9902377
- **Project number:** 5R01CA210806-04
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Keith Magnus Sigel
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $533,267
- **Award type:** 5
- **Project period:** 2017-04-13 → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9902377

## Citation

> US National Institutes of Health, RePORTER application 9902377, Optimizing Lung Cancer Treatment in HIV Infected Persons (5R01CA210806-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9902377. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*